Rhythm Pharmaceuticals Inc (RYTM) - Net Assets
Based on the latest financial reports, Rhythm Pharmaceuticals Inc (RYTM) has net assets worth $139.07 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($481.19 Million) and total liabilities ($342.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore cash efficiency ratio of Rhythm Pharmaceuticals Inc to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $139.07 Million |
| % of Total Assets | 28.9% |
| Annual Growth Rate | N/A |
| 5-Year Change | -51.06% |
| 10-Year Change | 1805.84% |
| Growth Volatility | 567.77 |
Rhythm Pharmaceuticals Inc - Net Assets Trend (2012–2025)
This chart illustrates how Rhythm Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Rhythm Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Rhythm Pharmaceuticals Inc (2012–2025)
The table below shows the annual net assets of Rhythm Pharmaceuticals Inc from 2012 to 2025. For live valuation and market cap data, see RYTM market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $139.07 Million | -15.48% |
| 2024-12-31 | $164.55 Million | -3.07% |
| 2023-12-31 | $169.76 Million | -35.76% |
| 2022-12-31 | $264.26 Million | -7.00% |
| 2021-12-31 | $284.15 Million | +70.63% |
| 2020-12-31 | $166.53 Million | -40.74% |
| 2019-12-31 | $281.02 Million | +14.12% |
| 2018-12-31 | $246.26 Million | +70.08% |
| 2017-12-31 | $144.79 Million | +1884.21% |
| 2016-12-31 | $7.30 Million | -77.20% |
| 2015-12-31 | $32.00 Million | +9038.83% |
| 2014-12-31 | $-358.00K | +99.38% |
| 2013-12-31 | $-57.46 Million | -58.36% |
| 2012-12-31 | $-36.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rhythm Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 131487000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $67.00K | 0.05% |
| Other Comprehensive Income | $-796.00K | -0.57% |
| Other Components | $1.49 Billion | 1072.62% |
| Total Equity | $139.07 Million | 100.00% |
Rhythm Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Rhythm Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coromandel International Limited
NSE:COROMANDEL
|
$5.84 Billion |
|
Marfrig Global Foods S.A.
SA:MRFG3
|
$5.84 Billion |
|
Changzhou Xingyu Automotive Lighting Systems Co Ltd
SHG:601799
|
$5.84 Billion |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
$5.84 Billion |
|
Hengdian Group DMEGC Magnetics Co Ltd
SHE:002056
|
$5.84 Billion |
|
Flagstar Financial, Inc.
NYSE:FLG
|
$5.84 Billion |
|
Apar Industries Limited
NSE:APARINDS
|
$5.83 Billion |
|
Alkermes Plc
NASDAQ:ALKS
|
$5.83 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rhythm Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 164,549,000 to 139,069,000, a change of -25,480,000 (-15.5%).
- Net loss of 196,539,000 reduced equity.
- Dividend payments of 5,378,000 reduced retained earnings.
- New share issuances of 222,692,000 increased equity.
- Other comprehensive income decreased equity by 757,000.
- Other factors decreased equity by 45,498,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-196.54 Million | -141.32% |
| Dividends Paid | $5.38 Million | -3.87% |
| Share Issuances | $222.69 Million | +160.13% |
| Other Comprehensive Income | $-757.00K | -0.54% |
| Other Changes | $-45.50 Million | -32.72% |
| Total Change | $- | -15.48% |
Book Value vs Market Value Analysis
This analysis compares Rhythm Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 42.72x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.72 | $91.42 | x |
| 2013-12-31 | $-1.14 | $91.42 | x |
| 2014-12-31 | $-0.04 | $91.42 | x |
| 2015-12-31 | $3.14 | $91.42 | x |
| 2016-12-31 | $0.44 | $91.42 | x |
| 2017-12-31 | $5.42 | $91.42 | x |
| 2018-12-31 | $7.94 | $91.42 | x |
| 2019-12-31 | $7.72 | $91.42 | x |
| 2020-12-31 | $3.77 | $91.42 | x |
| 2021-12-31 | $5.73 | $91.42 | x |
| 2022-12-31 | $5.07 | $91.42 | x |
| 2023-12-31 | $2.94 | $91.42 | x |
| 2024-12-31 | $2.70 | $91.42 | x |
| 2025-12-31 | $2.14 | $91.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rhythm Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -141.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -103.57%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 3.46x
- Recent ROE (-141.32%) is below the historical average (-76.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.50 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.69 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.46 Million |
| 2015 | -34.60% | 0.00% | 0.00x | 1.16x | $-14.27 Million |
| 2016 | -354.56% | 0.00% | 0.00x | 1.69x | $-26.60 Million |
| 2017 | -23.28% | 0.00% | 0.00x | 1.05x | $-48.19 Million |
| 2018 | -30.08% | 0.00% | 0.00x | 1.06x | $-98.69 Million |
| 2019 | -47.91% | 0.00% | 0.00x | 1.10x | $-162.73 Million |
| 2020 | -78.50% | -373505.71% | 0.00x | 1.12x | $-147.38 Million |
| 2021 | -23.93% | -2156.21% | 0.01x | 1.16x | $-96.42 Million |
| 2022 | -68.54% | -766.22% | 0.06x | 1.45x | $-207.55 Million |
| 2023 | -108.79% | -238.52% | 0.23x | 1.96x | $-201.65 Million |
| 2024 | -158.37% | -200.27% | 0.33x | 2.38x | $-277.06 Million |
| 2025 | -141.32% | -103.57% | 0.39x | 3.46x | $-210.45 Million |
Industry Comparison
This section compares Rhythm Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc (RYTM) | $139.07 Million | 0.00% | 2.46x | $5.84 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more